drugset / Trial / NCT00111085

Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)

NCT00111085 ↗

Phase 2 Completed 413 enrolled Idorsia Pharmaceuticals Ltd.
RandomizedParallel-groupPrevention

Summary

The purpose of the study is to measure how effective and safe three different doses of the drug clazosentan are in preventing vasospasm after subarachnoid hemorrhage.

Timeline

Start
2005-01-10
Primary completion
2006-03-30
Completion
2006-03-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Clazosentan Small molecule 1 mg Intravenous
Subject Clazosentan Small molecule 5 mg Intravenous
Subject Clazosentan Small molecule 15 mg Intravenous